This contract research is to evaluate the therapeutic effects of Lead AusBio Ltd compounds in murine models of chronic AAD/asthma and pulmonary fibrosis, to determine the extent to which these compounds may be evaluated in a clinical setting.
|Short title||Evaluation of Lead AusBio Ltd Compounds|
|Effective start/end date||15/02/21 → 14/08/22|
- AusBio Limited: AUD329,977.00
- Pulmonary Fibrosis
- sialic glycoconjugates